Novartis patent case a blow to major drug firms

India’s top court has dismissed Swiss manufacturer Novartis’s attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generic equivalents.

In India, many patented drugs are unaffordable for most of its 1.2 billion people.